Protein C News and Research

RSS

Valproic acid can enhance neuronal regeneration following brachial plexus root avulsion

Brachial plexus root avulsion is the most serious type of peripheral nerve injury. Valproic acid has been shown to exert neuroprotective effects and promote neurite outgrowth in several peripheral nerve injury models. However, whether valproic acid can exert its beneficial effect on neurons after brachial plexus avulsion injury is currently unknown.

3 Dec 2013

Scientists explain new family of proteins that appear to play key role in cancer

Scientists have described a new family of proteins that appear to play a key role in cancer and might be targets for future cancer drugs.

3 Dec 2013

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Biogen Idec announced today that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application (BLA) for ALPROLIX, the company's investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.

2 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013

Four-drug regimen shows first-line efficacy in advanced NSCLC

A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers report.

2 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unnecessary operations.

2 Dec 2013

USC scientists show gene-environment interaction augments risk for developing autism

Exposure to air pollution appears to increase the risk for autism among people who carry a genetic disposition for the neurodevelopmental disorder, according to newly published research led by scientists at the Keck School of Medicine of the University of Southern California.

2 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

European Patent Office issues Notice of Grant to 22nd Century Group for NBB and A622 genes

22nd Century Group, Inc. today announced that the European Patent Office issued a Notice of Grant to the company for the NBB and A622 genes. Both genes are responsible for nicotine production in the tobacco plant.

30 Nov 2013

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Cyclin D1, a protein that helps push a replicating cell through the cell cycle also mediates the processing and generation of mature microRNA, according to new research publishing November 29 in Nature Communications. The research suggests that a protein strongly implicated in human cancer also governs the non-protein-coding genome. The non-coding genome, previously referred to as junk DNA, makes up most of the human genome, and unlike the coding genome, varies greatly between species.

29 Nov 2013

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Patrys Limited, a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Study brings effective hepatitis C cure closer to reality

Scientists at The Scripps Research Institute have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The new data reveal unexpected structural features of this protein and should greatly speed efforts to make an effective hepatitis C vaccine.

29 Nov 2013

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

A study led by researchers at Boston University School of Medicine demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth. The findings are published in the December issue of Science Signaling.

29 Nov 2013

Researchers identify gene responsible for malfunctions in fear-related memory system

A study published recently in the Journal of Neuroscience points, for the first time, to the gene trkC as a factor in susceptibility to the disease. The researchers define the specific mechanism for the formation of fear memories which will help in the development of new pharmacological and cognitive treatments.

29 Nov 2013

Scientists design small synthetic molecules capable of blocking AIDS virus replication

A multidisciplinary team of scientists from Spanish universities and research centres, among which is the University of Valencia, has managed to design small synthetic molecules capable of joining to the genetic material of the AIDS virus and blocking its replication.

28 Nov 2013

Childhood asthma, eczema linked to adolescent psychotic experiences

UK research indicates that children with asthma and eczema are significantly more likely to have psychotic experiences during adolescence, boosting a previously reported relationship between schizophrenia and atopic disorders.

28 Nov 2013

Research: Modification of SUMO protein plays vital role in normal brain function

Scientists are a step closer to understanding how some of the brain's 100 billion nerve cells co-ordinate their communication.

28 Nov 2013

Protein C News and Research

Valproic acid can enhance neuronal regeneration following brachial plexus root avulsion

Scientists explain new family of proteins that appear to play key role in cancer

FDA extends initial PDUFA date for Biogen Idec's review of ALPROLIX BLA

Newly identified protein could prove promising new drug target for AIDS

Four-drug regimen shows first-line efficacy in advanced NSCLC

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

New biomarkers to improve diagnostics of prostate cancer

USC scientists show gene-environment interaction augments risk for developing autism

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

European Patent Office issues Notice of Grant to 22nd Century Group for NBB and A622 genes

Cyclin D1 protein controls cell cycle progression, microRNA biogenesis in breast cancer

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Study brings effective hepatitis C cure closer to reality

Study reveals new mechanism that may block formation of new blood vessels and cancer growth

Researchers identify gene responsible for malfunctions in fear-related memory system

Scientists design small synthetic molecules capable of blocking AIDS virus replication

Childhood asthma, eczema linked to adolescent psychotic experiences

Research: Modification of SUMO protein plays vital role in normal brain function

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News